Abstract 779P
Background
HRD is used to identify HGOC patients most likely to benefit from PARPi. Unlike commercially available genomic scar HRD tests (CT), functional testing by RAD51, have potential to provide a real-time readout of actual HR status and may be more reliable to detect HRD.
Methods
This single-institution study assesses the immunofluorescence-based RAD51 foci test and correlates it to CT and treatment outcomes in newly diagnosed advanced HGOC pts between 2020-2023. Tumors with <10% RAD51+ tumor cells in S/G2-phase were classified as HRD positive (HRD+). HRD status agreement rate between CT and RAD51 was calculated. Median progression-free survival (mPFS) was estimated in each subgroup.
Results
Overall, 53 pts had CT and RAD51 tests performed on archival tumour samples. Both tests were contributive for 38 pts. As 1st line therapy, all pts received platinum chemotherapy. As maintenance, 47% received PARPi and 18% Bevacizumab alone. % of HRD+ according CT and RAD51 was 55.3% (21/38) and 42.1% (16/38), respectively. Concordance rate between both tests was 50% (95%CI 34.8-65.2), with 12 and 7 pts identified as HRD+ only by CT and RAD51. Table: 779P
HRD test | HRD RAD51 | HRP RAD51 |
HRD CT | 9 | 12 |
HRP CT | 7 | 10 |
Based on CT, mPFS of HRD+ and HRP pts was 19.4m and 16.1m, respectively (HR 0.69; 95%CI, 0.26-1.85). Based on RAD51, mPFS for HRD and HRP pts was 19.4m and 14.3m (HR 0.70; 95%CI, 0.25-1.93), respectively. Among pts with consistent HRD test results, mPFS was 19.4 m and 11 m for HRD and HRP pts, respectively. Among disparate results, mPFS was 17.4m and 16.1m for pts defined as HRD only by CT and RAD51, respectively.
Conclusions
Our preliminary data showed both tests identified HRD and HRP subpopulations with similar outcomes despite low correlation between them. Among pts with HRP by CT, RAD51 identified a subset of HRD+ with better mPFS. Combination of genomic and functional HRD tests could improve molecular diagnostic accuracy of HGOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
VHIO.
Disclosure
C. Garcia Duran: Financial Interests, Principal Investigator: AstraZeneca; Financial Interests, Speaker’s Bureau: GSK. G. Villacampa Javierre: Financial Interests, Personal, Invited Speaker, Invited speaker in a course: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Invited speaker in an internal training: Pierre Fabrer, GSK; Financial Interests, Personal, Invited Speaker, Internal discussion about the interpretation of some published results: Pfizer; Financial Interests, Personal, Other, Collaborations with specific projects: Reveal Genomics. L. Fariñas Madrid: Financial Interests, Invited Speaker: AstraZeneca; Financial Interests, Speaker’s Bureau: GSK. D.G. Illescas: Financial Interests, Invited Speaker: GSK. V. Serra Elizalde: Financial Interests, Research Grant: Novartis. A. Llop-Guevara: Financial Interests, Research Grant: PharmaMar. A. Oaknin: Financial Interests, Personal, Advisory Board: AstraZeneca, Clovis Oncology, Deciphera Pharmaceuticals, Genmab, GSK, Immunogen, Mersana Therapeutics, PharmaMar, Merck Sharps & Dohme de España, SA, Agenus, Sutro, Corcept Therapeutics, EMD Serono, Novocure, Sattucklabs, Itheos, Eisai, F. Hoffmann-La Roche, Seagen, OneXerna Therapeutics, Inc., Regeneron, Sutro Biopharma; Financial Interests, Personal, Other, Travel and accomodation: AstraZeneca, PharmaMar, Roche; Financial Interests, Institutional, Funding: Amgen, AbbVie Deutschland, Advaxis Inc., Aeterna Zentaris, Aprea Therapeutics AB, Regeneron Pharmaceuticals, Clovis Oncology Inc., EISAI limited Ltd., F. Hoffmann-La Roche Ltd., Immunogen Inc., Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc., PharmaMar SA, Tesaro Inc., Bristol Myers Squibb; Non-Financial Interests, Leadership Role, on behalf of GEICO: GCIG; Non-Financial Interests, Officer, Chair of Gynaecological Track ESMO 2019 . Scientific Track Member Gynaecological Cancers ESMO 2018 , ESMO 2020 , ESMO 2022 . Member of Gynaecological Cancers Faculty and Subject Editor Gyn ESMO Guidelines: ESMO; Non-Financial Interests, Leadership Role, ESMO GYN Co-Chair 2023-2025: ESMO; Non-Financial Interests, Leadership Role, Chair de Cervix Committee. 2022-2024: GCIG; Non-Financial Interests, Member: ESMO, ASCO, GCIG, SEOM, GOG. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11